Addus HomeCare
Addus HomeCare's revenue rose 23.2% to $1.4 billion in fiscal 2025. Its operating margin was 9.7%, up from 8.9% a year earlier. Free cash flow was $104 million, down 6.0%. The diluted share count rose 5.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Revenue and margins
Net income and earnings per share
From fiscal 2016 to 2025, earnings per share grew 19.3% a year and net income 25.7% a year, as new shares raised the share count by 63% and diluted each share's earnings.
Returns on capital
Cash flow
Payouts and share count
Valuation
Two ways to value Addus HomeCare yourself, both starting from its filings: a discounted cash flow model and the price-to-earnings method.
Discounted cash flow (DCF)
A discounted cash flow (DCF) model values a business as the cash it may generate in future, discounted back to today. The starting figures come from Addus HomeCare's 10-K (or, for net cash and shares, its latest 10-Q) and the assumptions are yours: start from one of three example scenarios, then change any figure to see what it implies for a share, and how that compares with the last share price.
Value per share on three example scenarios, from Addus HomeCare's fiscal 2025 free cash flow of $104M, net cash of −$39M at December 31, 2025 and 18 million diluted shares, from its filings. The scenarios are fitted to Addus HomeCare: the base scenario's growth in years 1 to 5 is its revenue growth over the last 3 years, 14.4% a year; the cautious and optimistic ones are lower and higher, and growth in years 6 to 10 is halfway to the long-run rate. The base scenario's discount rate is 8%: 7% for a stable business (Health Care Services), plus 1 point as a smaller company, worth $2.2B; the cautious and optimistic ones use a point more and a point less. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.
- Last close, October 26, 2026
- $121.17
- Value on these assumptions, against the last close
- —
- Cash flows in years 1 to 10, valued today
- —
- Everything after year 10, valued today
- —
- Plus net cash
- —
- Share of value from after year 10
How the value changes with two assumptions
Price-to-earnings (P/E) method
Another common way to value a company is to multiply its earnings per share by a price-to-earnings (P/E) multiple: the number of years of today's earnings an investor pays for a share. A higher multiple usually means investors expect earnings to grow. Choose a multiple, for example from similar companies, to see the value it gives.
Value per share on three example scenarios, from Addus HomeCare's earnings per share of $5.71 (over the last four quarters). Each grows earnings for a year at the cash flow scenarios' rates and applies a multiple to next year's earnings: 28×, the middle of Addus HomeCare's own P/E today, its peers' median and its sector's median (the Health Care median) for the base scenario, 20% less and more for the cautious and optimistic ones. The price is brought back a year at 9%, 8% and 7%. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.
- Last close, October 26, 2026
- $121.17
- Value at this multiple, against the last close
- —
- Addus HomeCare's P/E at the last close
- 21.2×
| Company | Last close | Earnings per share | P/E today |
|---|---|---|---|
| Lifestance HealthLFST | $13.06 | $0.13 | 100.5× |
| CorVelCRVL | $84.59 | $2.25 | 37.6× |
| Sotera HealthSHC | $18.39 | $0.57 | 32.3× |
| Addus HomeCareADUS | $121.17 | $5.71 | 21.2× |
Balance sheet
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 169 | 80 | 65 | 99 | 82 |
| Debt incl. finance leases | 221 | 132 | 124 | 218 | 121 |
| Net debt (negative means net cash) | 52 | 52 | 59 | 120 | 39 |
| Net debt to EBITDA | 0.7x | 0.6x | 0.6x | 1.0x | 0.2x |
| Debt to equity | 0.4x | 0.2x | 0.2x | 0.2x | 0.1x |
| Interest coverage | 11.4x | 7.7x | 8.2x | 13.3x | 10.2x |
| Current ratio | 2.8x | 1.7x | 1.4x | 1.7x | 1.8x |
| Quick ratio | 2.8x | 1.7x | 1.4x | 1.7x | 1.8x |
Insider trades
Over the 12 months between October 27, 2025 and October 26, 2026, no insider bought Addus HomeCare shares on the open market, and 11 insiders sold $5.3 million, $3.0 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 22, 2026 | Heather Brianne DixonPresident and Chief Operating | Sold plan | 288 | $93.77 | $27,006 | Form 4 |
| May 21, 2026 | Esteban LopezDirector | Sold | 250 | $93.00 | $23,250 | Form 4 |
| May 19, 2026 | Esteban LopezDirector | Sold | 250 | $93.00 | $23,250 | Form 4 |
| Apr 21, 2026 | Cliff Donald BlessingEVP, Chief Development Officer | Sold plan | 178 | $93.61 | $16,663 | Form 4 |
| Mar 2, 2026 | Monica RainesEVP, CCO and Quality Officer | Sold plan | 224 | $102.15 | $22,882 | Form 4 |
| Feb 25, 2026 | Allison R DirkChairman and CEO, Director | Sold plan | 2,364 | $105.36 | $249,071 | Form 4 |
| Feb 25, 2026 | Brian PoffEVP, Chief Financial Officer | Sold plan | 820 | $105.36 | $86,395 | Form 4 |
| Feb 25, 2026 | Sean GaffneyEVP, Chief Legal Officer | Sold plan | 442 | $105.36 | $46,569 | Form 4 |
| Feb 25, 2026 | Darby AndersonEVP, Chief Govt Rel Officer | Sold plan | 396 | $105.36 | $41,723 | Form 4 |
| Feb 25, 2026 | David W. TuckerEVP, Chief Strategy Officer | Sold plan | 379 | $105.36 | $39,931 | Form 4 |
| Feb 25, 2026 | Michael D. WattenbargerEVP, Chief Information Officer | Sold plan | 300 | $105.36 | $31,608 | Form 4 |
| Feb 25, 2026 | Roberton James StevensonEVP, Chief HR Officer | Sold plan | 284 | $105.36 | $29,922 | Form 4 |
Piotroski F-score
The F-score counts how many of nine simple tests of profitability, funding and efficiency a company passed in a year (Piotroski, 2000). The more tests passed, the stronger the year: 8 or 9 is strong, 0 to 2 weak. Companies that report no gross profit are scored on the other eight.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Fail | Pass |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Pass | Fail | Fail |
| F-score | 7 of 9 | 6 of 9 | 5 of 9 |
| Accruals ratio | −5.1% | −3.5% | −1.1% |
Compare
Put Addus HomeCare side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Addus HomeCare | FY25 | 23.2% | 9.7% | 7.3% | 9.4% | 0.2x | 5 | |
| Lifestance Health | FY25 | 13.8% | 1.7% | 7.7% | 1.2% | 0.5x | 7 | Compare |
| Tempus AI | FY25 | 83.4% | −19.9% | −18.8% | — | — | 5 | Compare |
| Sotera Health | FY25 | 5.7% | — | 12.8% | 6.7% | — | 7 | Compare |
| CorVel | FY26 | 7.0% | — | 11.5% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 401 | 426 | 517 | 649 | 765 | 864 | 951 | 1,059 | 1,155 | 1,422 |
| Revenue growth | — | 6.2% | 21.3% | 25.6% | 17.9% | 13.0% | 10.0% | 11.3% | 9.1% | 23.2% |
| Gross profit | 106 | 116 | 137 | 179 | 226 | 270 | 300 | 340 | 375 | 462 |
| Research and development | — | — | — | — | — | — | — | — | — | — |
| Operating income | 16 | 25 | 23 | 35 | 44 | 66 | 69 | 91 | 103 | 139 |
| Net income | 12 | 12 | 16 | 25 | 33 | 45 | 46 | 62 | 74 | 96 |
| Diluted EPS (US$) | 1.07 | 1.03 | 1.33 | 1.77 | 2.08 | 2.81 | 2.84 | 3.83 | 4.23 | 5.22 |
| Diluted shares (millions) | 11 | 12 | 12 | 14 | 16 | 16 | 16 | 16 | 17 | 18 |
| Cash flow | ||||||||||
| Cash from operations | −1 | 53 | 33 | 12 | 109 | 40 | 105 | 112 | 116 | 112 |
| Capital expenditure | 2 | 4 | 5 | 5 | 7 | 5 | 8 | 10 | 6 | 8 |
| Free cash flow | −2 | 49 | 28 | 7 | 103 | 35 | 97 | 103 | 110 | 104 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 20 | 24 | 62 | 184 | 208 | 37 | 98 | 110 | 354 | 0 |
| Stock-based compensation | 1 | 3 | 4 | 6 | 6 | 9 | 11 | 10 | 11 | 16 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 8 | 54 | 70 | 112 | 145 | 169 | 80 | 65 | 99 | 82 |
| Debt incl. finance leases | 25 | 43 | 17 | 60 | 195 | 221 | 132 | 124 | 218 | 121 |
| Total assets | 230 | 272 | 348 | 637 | 893 | 948 | 938 | 1,024 | 1,413 | 1,437 |
| Total liabilities | 72 | 95 | 80 | 161 | 374 | 373 | 304 | 318 | 442 | 352 |
| Shareholders' equity | 155 | 170 | 268 | 476 | 519 | 574 | 634 | 707 | 970 | 1,085 |
| Margins and ratios | ||||||||||
| Gross margin | 26.5% | 27.2% | 26.5% | 27.6% | 29.6% | 31.2% | 31.5% | 32.1% | 32.5% | 32.5% |
| Operating margin | 3.9% | 5.9% | 4.4% | 5.4% | 5.8% | 7.6% | 7.2% | 8.6% | 8.9% | 9.7% |
| Net margin | 3.0% | 2.8% | 3.2% | 3.9% | 4.3% | 5.2% | 4.8% | 5.9% | 6.4% | 6.7% |
| Free cash flow margin | −0.6% | 11.5% | 5.4% | 1.1% | 13.4% | 4.0% | 10.2% | 9.7% | 9.6% | 7.3% |
| Return on capital | 7.4% | 8.6% | 9.7% | 8.5% | 7.1% | 8.2% | 8.0% | 9.6% | 8.2% | 9.4% |
| Return on equity | 8.2% | 7.4% | 7.5% | 6.8% | 6.7% | 8.3% | 7.6% | 9.3% | 8.8% | 9.3% |
| Return on assets | 5.8% | 4.8% | 5.3% | 5.1% | 4.3% | 4.9% | 4.9% | 6.4% | 6.0% | 6.7% |
| Net debt to EBITDA | 0.8x | −0.3x | −1.7x | −1.1x | 0.9x | 0.7x | 0.6x | 0.6x | 1.0x | 0.2x |